1. U.S. Food and Drug Administration.Model‐informed drug development pilot program (August2018). Accessed September 4 2018.
2. U.S. Food and Drug Administration.Draft guidance for industry: bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA (December2013). Accessed September 4 2018.
3. U.S. Food and Drug Administration.Draft guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs—general considerations (March2014). Accessed September 4 2018.
4. U.S. Food and Drug Administration.Draft guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations (July2002). Accessed September 4 2018.
5. U.S. Food and Drug Administration.Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate‐release solid oral dosage forms based on a biopharmaceutics classification system (December2017). Accessed September 4 2018.